Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease

Trial Profile

Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jul 2008 The expected completion date for this trial has been extended from Jun 2009 to Feb 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top